Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Baxter to reconsider AD program after late-stage trial failure
June 2013
SHARING OPTIONS:

NEW YORK—Baxter International Inc. has announced the failure of Gammagard, its antibody treatment for Alzheimer's, in late-stage trials. Though the drug did show some benefit in patients with moderate disease and those who carry the ApoE4 gene, which is known to increase the risk of Alzheimer's disease, Gammagard failed to engender a significant benefit in terms of cognitive decline and functional ability in patients, the trial's main endpoints. Seventeen serious adverse reactions, which were considered to be treatment-related, were observed in the trials, but Ludwig Hantson, president of Baxter's bioscience business, noted in a conference call that the study was generally well tolerated. Hanston said the company is "re-evaluating our approach," and Baxter is likely to make a decision on proceeding with the program by the end of the year.  

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.